Metaclopramide Hydrochloride is a defined ionic salt form offering distinct advantages in pharmaceutical processing and performance over the free acid or base. The counter-ion in Metaclopramide Hydrochloride has been selected based on toxicological acceptability at daily intake levels achievable from the proposed dosage regimen, and compatibility with the drug product excipient matrix. Solid-state characterisation of Metaclopramide Hydrochloride includes polymorph screening, stability under accelerated conditions, and determination of hygroscopic behaviour that may affect powder processing, fill weight uniformity, and long-term chemical stability in the drug product.
Genotoxicity data for Metaclopramide Hydrochloride are assessed under the ICH M7 framework for carcinogenic impurity qualification. A positive Ames test result without a clear non-genotoxic mechanism triggers linear extrapolation from carcinogenicity data, with the acceptable intake derived from the TD50 or the default value of 1.5 µg/day for lifet
